

INTRODUCTION

The INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System* provides all enzymes and enzyme-related reagents for making N1-methyl-pseudouridine (N1meΨ)-containing, 5'-capped, 3'-polyadenylated mRNA with greatly reduced double-stranded RNA (dsRNA) content, lower than what can be achieved with special T7 RNA polymerase mutants. The kit includes modules for (i) *in vitro* transcription of linear double-stranded DNA templates using the T7 mScript Enzyme Solution, the canonical nucleotides ATP, CTP, GTP and the modified nucleotide N1-methyl-pseudouridine-5'-triphosphate (N1meΨTP), (ii) enzymatic capping of the RNA using the ScriptCap™ Cap 1 Capping System (contains both ScriptCap Capping Enzyme and 2'-O-Methyltransferase) for making mRNA with a Cap 1 cap structure, (iii) A-Plus™ Poly(A) Polymerase for adding a 3'-poly(A) tail, (iv) enzymatic removal of dsRNA content using the Min-Immune™ Gold dsRNA Removal system and (v) 5 M NH₄OAc as a convenient RNA/mRNA purification method.

Post-transfection, capped and tailed mRNA has increased stability and translation efficiency in most eukaryotic cell lines. Additionally, it has been shown that N1meΨ-mRNAs are translated into protein at higher levels and induce lower innate immune responses in human and other mammalian cells that express various RNA sensors compared to corresponding unmodified mRNAs.¹⁻⁶ The INCOGNITO mScript System generates modified mRNA with virtually 100% transcript capping and user-defined poly(A) tail length. Poly(A) tail lengths can be generated much longer than is possible using a template-encoded tail, even greater than 300-A's. Additionally, the removal of dsRNA from mRNA preparations has been shown to be essential for reducing the innate immunogenic response to the mRNA in cells.⁷⁻¹⁰ Alternative dsRNA removal methods, such as reverse-phase HPLC¹¹, hydroxyapatite chromatography¹² and cellulose chromatography¹³, are associated with high capital costs as well as reduced final product yields. The Min-Immune Gold dsRNA Removal system provides an easy to use method for removing the dsRNA content of mRNA preps without a reduction of the single-stranded mRNA yield. INCOGNITO Complete N1meΨ-mRNA is suitable for use in transfection and microinjection experiments as well as *in vitro* translation systems.

* see patent and license information on page 30.

MATERIALS

Materials Supplied

Important Store at –20°C in a freezer without a defrost cycle. Do not store at –70°C.



T7 mScript™ <i>In vitro</i> Transcription Module (Module 1 of 5) INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System Kit Contents 25 reactions		
Kit Module	Kit Component	Reagent Volume
<i>In Vitro</i> Transcription	T7 mScript™ Enzyme Solution	50 µl
	10X T7 mScript™ Transcription Buffer II	50 µl
	100 mM Dithiothreitol (DTT)	50 µl
	N1meΨTP PreMix 25 mM each GTP, ATP, N1meΨTP, CTP	180 µl
	RNase-Free DNase I, 1 U/µl	25 µl

ScriptCap™ Cap 1 Capping Module (Module 2 of 5) INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System Kit Contents 25 reactions		
Kit Module	Kit Component	Reagent Volume
Post- Transcriptional Capping	ScriptCap™ Capping Enzyme, 10 U/µl	100 µl
	ScriptCap™ 2'-O-Methyltransferase, 100 U/µl	100 µl
	10X ScriptCap™ Capping Buffer 0.5 M Tris-HCl (pH 8.0), 60 mM KCl and 12.5 mM MgCl ₂	250 µl
	20 mM S-adenosyl-methionine (SAM)	125 µl
	20 mM GTP	125 µl

A-Plus™ Poly(A) Tailing Module (Module 3 of 5) INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System Kit Contents 25 reactions		
Kit Module	Kit Component	Reagent Volume
Poly(A)- Tailing	A-Plus™ Poly(A) Polymerase, 4 U/µl	130 µl
	10X A-Plus™ Poly(A) Tailing Buffer 0.5 M Tris-HCl (pH 8.0), 2.5 M NaCl and 100 mM MgCl ₂	300 µl
	20 mM ATP	150 µl

For more information, consult the appropriate safety data sheet (SDS) at www.cellscript.com.

Component list continued on next page.

Min-Immune™ Gold dsRNA Removal Module (Module 4 of 5) INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System Kit Contents 25 reactions		
Kit Module	Kit Component	Reagent Volume
dsRNA Removal	Min-Immune™ Gold RNase III (20X)	150 µl
	Min-Immune™ Gold 10X RNase III Treatment Buffer	300 µl

INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA (Module 5 of 5) Production System Kit Contents 25 reactions		
Kit Module	Kit Component	Reagent Volume
Common Usage	ScriptGuard™ RNase Inhibitor, 40 U/µl	165 µl
	RNase-Free Water	12 ml
	5 M Ammonium Acetate	12 ml

T7 Control Template DNA: Is a linearized 4.1 kb plasmid that contains a T7 promoter followed by a phage lambda dsDNA insert that encodes a 1,375 base runoff transcript. The Control Template DNA is provided at a concentration of 0.5 µg/µl in T₁₀E₁ Buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA).

Materials Required, but not Supplied

- A DNA template for transcription of your RNA of interest.
- Materials or kits for purification of the RNA product if not using the kit provided NH₄OAc. (For suggestions, see RNA Purification, pages 25-26).
- RNase-free TE Buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) **for final mRNA resuspension-only**, if not using the kit provided RNase-Free Water.
- 70% ethanol

Optional Materials

- dsRNA-specific detection system including:
 - dsRNA-specific antibody (e.g., J2 antibody [Absolute Biotech-Exalpha])
 - Dot/slot blotting system for use with the antibody
 - An image analyzer for blot visualization and/or quantification
 - dsRNA standards
- TE saturated phenol/chloroform, 0.5-1 M EDTA

SPECIFICATIONS

Storage Buffers

RNase-Free DNase I is provided in a 50% glycerol solution containing 50 mM Tris-HCl, pH 7.5, 10 mM CaCl₂, 10 mM MgCl₂ and 0.1% Triton® X-100.

A-Plus Poly(A) Polymerase and Min-Immune Gold RNase III are provided in a 50% glycerol solution containing 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 mM DTT, 0.1 mM EDTA and 0.1% Triton X-100.

ScriptGuard RNase Inhibitor is provided in a 50% glycerol solution containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM DTT, 0.1 mM EDTA and 0.1% Triton X-100.

All other enzymes are provided in a 50% glycerol solution containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.1 mM EDTA and 0.1% Triton X-100.

Unit Definitions

One INCOGNITO T7 mScript Complete N1meΨ-mRNA Production System reaction produces 60 µg of N1meΨ-containing, 5'-capped, 3'-poly(A)-tailed, dsRNA-depleted mRNA.

One unit of RNase-Free DNase I digests 1 µg of pUC19 DNA to oligodeoxynucleotides in 10 minutes at 37°C.

One unit of ScriptCap Capping Enzyme releases 1 nmole of inorganic phosphate from GTP in 10 minutes at 37°C under standard assay conditions.

One unit of ScriptCap 2'-O-Methyltransferase methylates one picomole of a control Cap 0 RNA in 1 hour at 37°C under standard assay conditions.

One unit of A-Plus Poly(A) Polymerase converts 1 nmole of ATP into acid-insoluble material in 10 minutes at 37°C under standard assay reaction conditions.

One unit of ScriptGuard RNase Inhibitor results in 50% inhibition of 5 ng of RNase A. Activity is measured by the inhibition of hydrolysis of cyclic 2',3'-CMP by RNase A.

Functional Testing

The INCOGNITO T7 mScript Complete N1meΨ-mRNA Production System is functionally tested under standard reaction conditions using the T7 Control Template DNA. The *in vitro* transcription module must produce at least 50 µg of RNA from 1 µg of the T7 Control Template DNA in 20 minutes at 37°C. A-Plus Poly(A) Polymerase is functionally tested in 1X A-Plus Poly(A) Tailing Buffer with 1 mM ATP and a 1.4 kb transcript. The capping and dsRNA removal module enzymes are tested independently using non-T7 control transcript RNA to assay for completeness of reaction.

Contaminating Activity Assays

All components of the INCOGNITO T7 mScript Complete N1meΨ-mRNA Production System are free of detectable RNase and DNase activity, except for the inherent activity of the RNase-Free DNase I and Min-Immune Gold RNase III components.

BEFORE YOU START: IMPORTANT TIPS FOR OPTIMAL RESULTS

◆ Cap 0- vs. Cap 1-mRNA:

The difference between Cap 0- and Cap 1-mRNA is the addition of a methyl group at the 2'-O position of the penultimate (second from the 5' end) nucleotide of the transcript (see Figures 1A and 1B). This methylation is part of the natural capping process in higher eukaryotic cells and in some but not all cases improves *in vivo* translation versus the corresponding Cap 0-mRNA.

The ScriptCap Capping Enzyme and ScriptCap 2'-O-Methyltransferase work together to produce the Cap 1 structure. To obtain a Cap 0 structure, simply omit the ScriptCap 2'-O-Methyltransferase from the reaction. When using a new cell line or translation system, we recommend performing a comparison between Cap 0- and Cap 1-mRNA translation efficiencies to determine the optimal cap structure for that system.

Figure 1A Cap 0-mRNA





Figure 1B Cap 1-mRNA



◆ Maintaining an RNase-Free Environment:


Highly stable RNases are ubiquitous, including on human skin.

Creating an RNase-free work environment and maintaining RNase-free solutions is critical for successful work with RNA.

We strongly recommend to:

- Use RNase-free tubes and pipette tips.
- Always wear gloves when handling kit components or samples containing RNA and change gloves frequently, especially after touching potential sources of RNase contamination such as doorknobs, pens, pencils and human skin. Do not touch any kit component or tube containing RNA with an ungloved hand.
- Keep all kit components tightly sealed when not in use. Keep all tubes containing RNA tightly sealed during the incubation steps.

Figure 2. INCOGNITO T7 mScript Complete N1meΨ-mRNA Production System Procedure



INCOGNITO T7 mSCRIPT Complete N1meΨ-mRNA PRODUCTION PROCEDURE OUTLINE**Synthesis of IVT N1meΨ-RNA****DNase I Treatment of IVT Reaction****Purification of the Transcription Product****Synthesis of Capped N1meΨ-RNA****Synthesis of Poly(A)-Tailed N1meΨ-RNA****Purification of the Capped & Tailed mScript N1meΨ-mRNA****Min-Immune Gold dsRNA Removal Treatment****Purification of the Capped & Tailed mScript Complete N1meΨ-mRNA**

An abbreviated procedure for experienced users of this kit can be found in the Technical Appendix.

BEFORE YOU START: IMPORTANT TIPS FOR OPTIMAL *IN VITRO* TRANSCRIPTION**◆ Template Requirements:**

The optimal templates for *in vitro* transcription are linear double-stranded DNA (dsDNA) molecules with 5'-protruding ends. DNA templates with blunt ends are less preferable and **templates with 3'-protruding ends should not be used**.

Transcription templates can be prepared from clones of the DNA to be transcribed in plasmids or other circular dsDNA vectors by linearizing the vectors downstream of the cloned DNA using a suitable restriction endonuclease or other means.

Alternatively, transcription templates can be generated by PCR amplification of RNA or DNA of interest using a strategy that results in joining of a T7 promoter to the appropriate end of the PCR product (e.g., wherein, the T7 promoter is either joined to the DNA or RNA that is amplified or is incorporated into one of the PCR primers).

◆ Template Efficiency and Incubation Time:

60 µg of IVT RNA are recommended for treatment in the subsequent capping and tailing reactions. The T7 Control Template DNA produces >60 µg of a ~1.4 kb RNA per 1 µg of DNA template in a 30 minute reaction.

However, yields vary for different templates based on the template sequence, structure, length, purity and the sequence and length of the particular RNA polymerase promoter. Examples of contaminants that can affect transcription yield include RNase, phenol, trace metals and SDS. See the Technical Appendix for suggestions related to template purification.

PROCEDURE

A. Synthesis of IVT N1meΨ-RNA

The *In Vitro* Transcription and Common Usage Modules are required for this portion of the procedure.

1. Set up the transcription reaction **at room temperature** by adding the reagents **in the order indicated below**:

INCOGNITO T7 mScript IVT Reaction	
Component	Amount
RNase-Free Water	x μl
Linearized template DNA with T7 RNAP promoter	1 μg
10X T7 mScript Transcription Buffer II	2 μl
N1meΨTP PreMix	7.2 μl
100 mM DTT	2 μl
ScriptGuard RNase Inhibitor	0.5 μl
T7 mScript Enzyme Solution	2 μl
Total Reaction Volume	20 μl

2. Incubate at 37°C for 15-30 minutes.

Important Assemble transcription reactions at room temperature in the order indicated at left. Assembly of transcription reactions at <22°C or in an alternate order, can result in the formation of an insoluble precipitate.



Transcription Buffer stored at -70°C may result in the formation of a white precipitate. To dissolve it, heat the tube at 37°C for 5 minutes and mix thoroughly.



One microgram of DNA template is recommended for most reactions. If the DNA template is <0.16 μg/μl, concentrate it, then resuspend in the appropriate amount of RNase-Free Water.

Important Use a 30 minute incubation when transcribing a template for the first time. Shorter incubation times can be used for subsequent transcription reactions once the yield characteristics of the template have been defined.

B. DNase I Treatment of IVT Reaction

1. DNase I treatment is used to remove the DNA template from the IVT reaction.

DNase I Treatment of IVT Reaction	
Component	Amount
IVT Reaction (from Step A)	20 μl
RNase-Free DNase I	1 μl
Total Reaction Volume	21 μl

2. Incubate for 15 minutes at 37°C.
3. Proceed to Purification of the Transcription Product.

C. Purification of the Transcription Product

The Common Usage Module is required for this portion of the procedure.

This step involves purification by ammonium acetate precipitation. It selectively precipitates RNA, while leaving most of the protein, DNA and unincorporated NTPs in the supernatant. Note: for this method, the RNA to be purified must be >100 bases in size. For alternative RNA purification methods, see Technical Appendix, RNA Purification, pages 25-26.

Ammonium Acetate Precipitation

1. Adjust reaction volume to 50 µl total using RNase-Free Water (add 29 µl to the reaction).
2. Add one volume (50 µl) of 5 M ammonium acetate. Mix well.
3. Incubate for 10-15 minutes on ice or at 4°C or at –20°C.
4. Pellet the RNA by centrifugation at >10,000 x g for 10 minutes at room temperature or at 4°C.
5. Remove the supernatant with a pipette and gently rinse the pellet with 70% ethanol to remove residual ammonium acetate.
6. Remove the 70% ethanol with a pipette without disturbing the RNA pellet.
7. Allow the RNA pellet to air dry, then resuspend in 50-75 µl of RNase-Free Water for quantitation.
Do not resuspend the RNA in an EDTA-containing solution.
8. Quantitate the RNA by spectrophotometry or fluorimetry.



Over dried pellets will be difficult to resuspend.



If desired, the RNA can now be frozen and stored overnight at –20°C.

BEFORE YOU START: IMPORTANT TIPS FOR OPTIMAL CAPPING**◆ Cap 0- vs. Cap 1-mRNA:**

The difference between Cap 0- and Cap 1-mRNA is the addition of a methyl group at the 2'-O position of the penultimate (second from the 5' end) nucleotide of the transcript (see Figures 1A and 1B). This methylation is part of the natural capping process in higher eukaryotic cells and in some but not all cases improves *in vivo* translation versus the corresponding Cap 0-mRNA.

The ScriptCap Capping Enzyme and ScriptCap 2'-O-Methyltransferase work together to produce the Cap 1 structure. To obtain a Cap 0 structure, simply omit the ScriptCap 2'-O-Methyltransferase from the reaction. When using a new cell line or translation system, we recommend performing a comparison between Cap 0- and Cap 1-mRNA translation efficiencies to determine the optimal cap structure for that system.

◆ SAM:

SAM slowly degrades over time at room temperature and above.
Keep thawed SAM solutions on ice at all times.

◆ RNA Source:

RNA produced in an *in vitro* transcription reaction should be purified and resuspended in RNase-Free Water prior to use in the ScriptCap Capping Enzyme System. **Do not resuspend the RNA in an EDTA-containing solution.**

◆ RNA Secondary Structure:

Some RNA transcripts can form stable secondary structures (homodimers and hairpins) involving the 5'-most nucleotides of the transcript severely limiting access of the 5'-most nucleotide to the ScriptCap Capping Enzyme. In order to increase the capping efficiency of such RNAs, use longer or hotter heat denaturation conditions than those noted in the protocol. Times and temperatures required will vary. In extreme cases, or when a heat denaturation step is not a viable option, reengineering of the 5' end sequence may be necessary to alleviate the secondary structure. This is often accomplished with a single point mutation within the first 5 bases of the transcript (non-coding region). Contact CELLSCRIPT Technical Services for suggestions and recommendations.

D. Synthesis of Capped N1meΨ-RNA

The Post-Transcriptional Capping and Common Usage Modules are required for this portion of the procedure.

1. The protocol below was designed to build a Cap 1 structure on the 5' end of 50-60 µg of uncapped N1meΨ-RNA. **If a Cap 0 structure is desired**, replace the ScriptCap 2'-O-Methyltransferase in Step 3 with an equivalent volume of RNase-Free Water.

Combine the following reagents:

INCOGNITO mScript Capping Reaction (step 1)	
Component	Amount
RNase-Free Water	x µl
<i>In vitro</i> transcribed N1meΨ-RNA, 50-60 µg	≤69.5 µl
Total Volume	69.5 µl



Heat-denaturation of the RNA is an optional step, but it is strongly recommended for RNAs which have not previously been characterized for their ease of enzymatic capping.

Important Only heat-denature the RNA and water components. **Do not** include any other reagent in this step.

2. Incubate at 65°C for 5-10 minutes, then transfer to ice.
3. While the heat-denatured RNA is cooling on ice, prepare a "Cocktail" of the following reaction components together in a separate tube.

INCOGNITO mScript Capping Reaction (step 3)	
Component	Amount
10X ScriptCap Capping Buffer	10 µl
20 mM GTP	5 µl
20 mM SAM	5 µl
ScriptGuard RNase Inhibitor	2.5 µl
ScriptCap 2'-O-Methyltransferase, (100 U/µl optional)	4 µl
Total Volume	26.5 µl



Important Do not include the ScriptCap Capping Enzyme in this mix.

Important Keep the thawed stock SAM solution on ice.



A white precipitate may form in the 10X ScriptCap Capping Buffer upon storage. To dissolve it, heat the tube at 37°C for 5 minutes and mix thoroughly.



If a Cap 0 structure is desired, replace the ScriptCap 2'-O-Methyltransferase with RNase-Free Water.

4. **Just prior to starting the reaction**, add the ScriptCap Capping Enzyme to the Cocktail from Step 3 and then combine this with the uncapped RNA solution from Step 1.

INCOGNITO mScript Capping Reaction (step 4)	
Component	Amount
Cocktailed reaction components (from step 3)	26.5 µl
ScriptCap Capping Enzyme (10 U/µl)	4 µl
Heat-denatured RNA (from step 1)	69.5 µl
Total Reaction Volume	100 µl



The efficiency of 2'-O-methylation can be lower if the RNA 5' end is structured. If your RNA is not completely 2'-O-methylated, we recommend increasing the incubation time to 2 hours. Also, since the concentration of methylation sites for a given mass is higher for small RNA than for large RNA, increase the reaction time for small RNA. For example, we suggest to increase the reaction time to 2 hours if your RNA is <730 nucleotides in length.

5. Incubate at 37°C for 30 minutes.
Longer incubation times, if desired, are acceptable.

6. Proceed directly to 3'-Poly(A)-Tailing. Purification of the RNA prior to the tailing step is **NOT** necessary. Alternatively, the unpurified capped RNA can be frozen and stored overnight at -20°C .

E. Synthesis of Poly(A)-Tailed N1meΨ-RNA

The Poly(A)-Tailing and Common Usage Modules are required for this portion of the procedure.

1. The protocol below was designed to produce ~150 b long poly(A) tails on 60 μg of capped N1meΨ-RNA.

Combine the following reagents:

INCOGNITO mScript Poly(A)-Tailing Reaction	
Component	Amount
5'-Capped <i>In vitro</i> transcribed N1meΨ-RNA (from Step D6)	100 μl
ScriptGuard RNase Inhibitor	0.5 μl
10X A-Plus Poly(A) Tailing Buffer	12 μl
20 mM ATP	6 μl
A-Plus Poly(A) Polymerase (4 U/μl)	5 μl
Total Volume	123.5 μl

Important Do not heat-denature the 5'-Capped *In vitro* transcribed RNA.

2. Incubate at 37°C for 30 minutes.
3. Stop the reaction using any one of the following methods:
- Proceed directly to Step F, Purification of the Capped and Tailed N1meΨ-mRNA (page 13).
 - Immediate storage at -20°C or -70°C .
 - Addition of EDTA to a final concentration of $>11\text{ mM}$.



To extend the poly(A) tail to $>200\text{ b}$, increase the incubation time to 60 minutes.

Important Do not stop the reaction by heat denaturation because it may degrade the RNA.



If desired, the RNA can now be frozen and stored overnight at -20°C .

F. Purification of the Capped and Tailed N1meΨ-mRNA

The Common Usage Module is required for this portion of the procedure.

This step involves purification by ammonium acetate precipitation. It selectively precipitates RNA, while leaving most of the protein, DNA and unincorporated NTPs in the supernatant. Note: for this method, the RNA to be purified must be >100 bases in size. For alternative RNA purification methods, see Technical Appendix, RNA Purification, pages 25-26.

1. Add one volume (124 μ l) of 5 M ammonium acetate to the reaction tube. Mix well.
2. Incubate for 10-15 minutes on ice or at 4°C or at –20°C.
3. Pellet the RNA by centrifugation at >10,000 x g for 10 minutes at room temperature or at 4°C.
4. Remove the supernatant with a pipette and gently rinse the pellet with 70% ethanol to remove residual ammonium acetate.
5. Remove the 70% ethanol with a pipette without disturbing the RNA pellet.
6. Allow the RNA pellet to air dry, then resuspend in 60 μ l RNase-Free Water for quantitation. **Do not resuspend the RNA in an EDTA-containing solution if proceeding to the dsRNA removal step.**
7. Quantitate the RNA by spectrophotometry or fluorimetry.



Over dried pellets will be difficult to resuspend.



If desired, the RNA can now be frozen and stored overnight at –20°C.

BEFORE YOU START: IMPORTANT TIPS FOR dsRNA REMOVAL**◆ RNA Source:**


It is important that the RNA is resuspended in RNase-free Water and NOT in an EDTA-containing solution such as T₁₀E₁ buffer.

◆ Treatment of single-stranded RNAs (ssRNA) containing inherent double-stranded regions:

The Min-Immune Gold dsRNA Removal system was designed to remove the contaminating dsRNA-content, produced as a transcription reaction byproduct, from the desired ssRNA transcription reaction product. However, some RNAs naturally contain dsRNA regions or structures within them. Some of these are vital functional components of the RNA (e.g., cellular factor binding sites). The lengths of these dsRNA regions dictate their sensitivity to both Min-Immune Gold RNase III cleavage (see Example Data on the following pages) as well as to recognition by intracellular dsRNA-specific pattern recognition receptors. **Because of this, we recommend that all new RNA sequences to be treated with the Min-Immune Gold dsRNA Removal system be characterized for Min-Immune Gold RNase III cleavage sensitivity by performing a 1X (or smaller) reaction treatment followed by analysis via denaturing agarose gel electrophoresis of treated versus non-treated samples prior to treatment of larger amounts of the same RNA.** See Example Data on the following pages.

Example Data:**Figure 3**


Formaldehyde-denaturing 1% agarose gel.
Two different treated Ψ-mRNA samples.
Standard image exposure (Syngene® G:Box).



Min-Immune Gold dsRNA Removal system treated RNAs, in this example: pseudouridine-containing mRNAs, should appear as single full-length bands of ssRNA lacking any background banding pattern that was not present in the untreated RNA sample.

Figure 4

Formaldehyde-denaturing 1% agarose gel.
Treated Ψ-mRNA sample.
Image over exposure (Syngene G:Box).




Some RNA samples can form transient dsRNA regions (molecular breathing) during the reaction which are substrates for Min-Immune Gold RNase III cleavage. These will appear as faint less than full length background bands.

- **Blue** arrow = full length mRNA.
- **Red** arrows = cleaved RNA fragments from transient Min-Immune Gold RNase III sensitive sites.

This does not affect the bulk functionality of the treated RNA.

Figure 5

Formaldehyde-denaturing 1% agarose gel.
Treated & Untreated Ψ-mRNA sample.
Standard image exposure (Syngene G:Box).




Some RNA samples contain inherent stable dsRNA regions due to the sequence of the RNA which are substrates for Min-Immune Gold RNase III cleavage. These will appear as strong less than full length background bands along with a diminished full length RNA band.

- **Blue** arrow = full length mRNA.
- **Red** arrows = cleaved RNA fragments from inherent Min-Immune Gold RNase III sensitive sites.

This will greatly affect the bulk functionality of the treated RNA. See the Troubleshooting section for options on how to handle such RNAs.

Figure 6

Formaldehyde-denaturing 1% agarose gel.
Treated U-IVT RNA samples.
Standard image exposure (Syngene G:Box).



A 1.25-kb RNA construct was designed to contain an inherent dsRNA region which included either a 12-bp or 24-bp hairpin in the secondary structure, and treated with Min-Immune Gold RNase III.


- **Blue** arrow = full length RNA.
- **Red** arrows = cleaved RNA fragments from Min-Immune Gold RNase III sensitive sites.

Duplexes of 12-bp dsRNA are not recognized by Min-Immune Gold RNase III while duplexes of 24-bp dsRNA are recognized.

Figure 7

dsRNA immuno-dot blot assayed with dsRNA-specific J2 antibody detection using horseradish peroxidase and chemiluminescent detection.

1 µg of Untreated or Treated mRNA was blotted for each experimental sample.




- A) Example result of an mRNA prep where the dsRNA content is totally removed by treatment. This mRNA can be used for downstream applications.
- B) Example result of an mRNA prep where the mRNA contains an inherent dsRNA region which is not recognized by Min-Immune Gold RNase III but is recognized by the J2 antibody. This mRNA can be used for downstream applications. See Figure 8 below.
- C) Example result of an mRNA prep where the dsRNA content is not totally removed by treatment. This mRNA would require retreatment prior to many downstream applications.

Figure 8

dsRNA immuno-dot blot assayed with dsRNA-specific J2 antibody detection using horseradish peroxidase and chemiluminescent detection.

1 µg of Untreated or treated mRNA was blotted for each experimental sample.



Example result of an mRNA prep where the mRNA contains an inherent dsRNA region which is not recognized by Min-Immune Gold RNase III but is recognized by the J2 antibody. The dsRNA region could not be removed with two (2x) or three (3x) Min-Immune Gold RNase III treatments even with extended incubation times (1.5 & 3 hrs). This mRNA can be used for downstream applications.

G. Min-Immune Gold dsRNA Removal Treatment

1. Recommended: save an amount of untreated RNA to run on a denaturing agarose gel versus the treated RNA for post treatment RNA analysis.

For the RNA to be treated, combine the following reagents at room temperature in the order indicated below:

Min-Immune Gold dsRNA Removal Treatment Reaction	
Component	Amount
RNase-Free Water	x μl
Min-Immune Gold 10X RNase III Treatment Buffer	12 μl
ScriptGuard RNase Inhibitor	3 μl
60 μg mScript N1meΨ-mRNA (from Step F7, page 13)	y μl
Min-Immune Gold RNase III (20X)	6 μl
Total Volume	120 μl

2. Incubate at 37°C for 60 minutes.
3. Proceed to Purification of the Capped & Tailed mScript Complete N1meΨ-mRNA.

H. Purification of the Capped & Tailed mScript Complete N1meΨ-mRNA

Before use in *in vivo* and *in vitro* translation systems, the capped and tailed N1meΨ-mRNA needs to be purified. We recommend the following protocol. This step involves purification by ammonium acetate precipitation. It selectively precipitates RNA, while leaving most of the protein, DNA and unincorporated NTPs in the supernatant. Note: for this method, the RNA to be purified must be >100 bases in size. For alternative RNA purification methods, see Technical Appendix, RNA Purification, pages 25-26.

1. Add one volume (120 μl) of 5 M ammonium acetate to the reaction tube. Mix well.
2. Incubate for 10-15 minutes on ice or at 4°C or at –20°C.
3. Pellet the RNA by centrifugation at >10,000 x g for 10 minutes at room temperature or at 4°C.
4. Remove the supernatant with a pipette and gently rinse the pellet with 70% ethanol to remove residual ammonium acetate.
5. Remove the 70% ethanol with a pipette without disturbing the RNA pellet.
6. Allow the RNA pellet to air dry, then resuspend in 30-60 μl RNase-Free Water, T₁₀E₁ or other suitable buffer for quantitation.
7. Quantitate the RNA by spectrophotometry or fluorimetry.
8. While usually unnecessary, steps 1-7 may be repeated a second time for even cleaner RNA.



Over dried pellets will be difficult to resuspend.

TROUBLESHOOTING
Synthesis of IVT RNA

Symptom	Solution
Low yields or less than full-length transcripts	Cleanup the templates to remove any RNase or other contaminants (see Technical Appendix for procedure).
	Verify that ScriptGuard RNase Inhibitor was added to the reaction.
	Extend the incubation time. Do not extend the reaction time beyond 3 hours.
	Increase the template concentration.
	Increase the reaction temperature to 42°C.
Assembled reaction formed an insoluble precipitate	Repeat assembly of the reaction at >22°C.
White precipitate in reaction buffer	Incubate the reaction buffer at 37°C for 5 minutes then mix thoroughly to dissolve the precipitate.
	Do not store the kit at –70°C.

Synthesis of Capped RNA

Symptom	Solution
Low capping efficiency	Cleanup the templates to remove any RNase or other contaminants.
	Verify that ScriptGuard RNase Inhibitor was added to the reaction.
	SAM slowly degrades at room temperature and above. Keep SAM solutions on ice at all times.
	Increase the capping reaction incubation time. For example, up to 3 hours at 37°C.
	Some RNAs form stable structures (e.g., homodimers, hairpins) at the 5' end, limiting access by Capping Enzyme or 2'-O-Methyltransferase. Analyze the sequence and increase the RNA denaturation temperature to above the T _m (e.g., to 65°C for 20 min, 75°C for 10 min, 85°C for 5 min). If the 5' end is highly structured, it might be necessary to modify the 5' end sequence using molecular biology techniques. Often this can be accomplished by making a single point mutation within the first 5 bases of the DNA template for the RNA transcript (non-coding region). Contact CELLSCRIPT Technical Services for suggestions and recommendations.
White precipitate in reaction buffer	Incubate the reaction buffer at 37°C for 5 minutes then mix thoroughly to dissolve the precipitate.
	Do not store the kit at –70°C.

TROUBLESHOOTING
Synthesis of Poly(A)-Tailed RNA

Symptom	Solution
Poly(A) tails are longer than expected	Decrease the time of incubation of the reaction.
	Decrease the amount of A-Plus Poly(A) Polymerase used in the reaction.
Poly(A) tails are shorter than expected	Increase the time of incubation of the reaction.
	Increase the amount of A-Plus Poly(A) Polymerase used in the reaction.
No Poly(A) tails are observed	Enzyme is inactive. Store only at –20°C. Keep on ice when not in the freezer.
	ATP is hydrolyzed. Do not expose to elevated temperatures.

dsRNA Removal

Symptom	Solution
Faint, minor, less than full length background bands are seen on the gel post-treatment	RNA samples were not fully denatured. • Be sure to be running a denaturing agarose gel. • Rerun the samples with an increased heat denaturing step prior to gel loading.
	RNA sample formed transient dsRNA regions (molecular breathing) during the reaction which were substrates for Min-Immune Gold RNase III cleavage. • See example Fig 4, page 15. • If very minor, no further treatment nor treatment changes are needed. • If minor, treat subsequent samples of this RNA more gently. Reduce incubation to 30 minutes or reduce the amount of Min-Immune Gold RNase III used by 50%.
Strong, major, less than full length background bands are seen on the gel post-treatment	RNA sample contained an inherent stable dsRNA region of sufficient length to be a substrate for Min-Immune Gold RNase III cleavage. • See example Figs 5 & 6, page 16. • The Min-Immune Gold dsRNA Removal system is not appropriate for treating this particular RNA sequence. If the dsRNA structure is crucial to RNA functionality, use an alternative method for dsRNA removal. If the dsRNA structure is not crucial to RNA functionality, mute the dsRNA structure to remove the duplex formation by altering the RNA sequence and retreat the new RNA.

TROUBLESHOOTING
dsRNA Removal (continued)

Symptom	Solution
dsRNA assessment indicates remaining dsRNA content	RNA contains a region of dsRNA. • See example Figs 7 & 8, page 17. • dsRNA region may be inherent to the RNA sequence and recognizable by the dsRNA-specific antibody but may not be recognizable by the Min-Immune Gold RNase III or intracellular dsRNA-specific pattern recognition receptors. • If very minor, no further treatment nor treatment changes are needed. • If minor, the RNA sample may be retreated with Min-Immune Gold RNase III. If the dsRNA assessment still shows dsRNA content after retreatment, then the dsRNA region is most likely inherent to the RNA sequence. Try the RNA in the downstream application. If the dsRNA assessment now shows virtually no dsRNA, the next time that specific RNA is to be made, more strongly treat the RNA by extending the incubation time to 2 or 3 hours or increasing the amount of Min-Immune Gold RNase III used in the reaction.
	Abnormally high amounts of dsRNA were present in the RNA sample. • Retreat the RNA sample. • The next time that specific RNA is to be made, more strongly treat the RNA by extending the incubation time to 2 or 3 hours or increasing the amount of Min-Immune Gold RNase III used in the reaction. • Consider using an altered transcription protocol that would produce less dsRNA during the IVT reaction.
	Min-Immune Gold dsRNA Removal reaction was inefficient or failed. • Retreat the RNA sample. If the problem persists contact CELLSCRIPT Technical service.

RELATED PRODUCTS

- EZ-QC™ mRNA Cap 1 Efficiency Assay Kit
- EZ-QC™ mRNA Capping Efficiency Assay Kit
- EZ-QC™ mRNA Poly(A) Tail Length Assay Kit
- EZ-QC™ XBG mRNA Capping Efficiency Assay Kit
- INCOGNITO™ T7 mScript™ Complete Ψ-mRNA Production System
- T7 mScript™ Complete Standard mRNA Production System

REFERENCES

1. Karikó, K. et al., (2008) *Molecular Therapy* 16, 1833.
2. Anderson, B.R. et al., (2010) *Nucl. Acids Res.* 17, 5884.
3. Karikó, K. et al., (2005) *Immunity* 23, 165.
4. Karikó, K. and Weissman, D. (2007) *Curr. Opin. Drug Discov. Devel.* 10, 523.
5. Andries, O. et al., (2015) *J. Controlled Release* 217, 337.
6. Svitkin, Y. V. et al., (2017) *Nucleic Acids Res.* 45 (10), 6023.
7. Karikó, K. et al., (2011) *Nucleic Acids Res.* 39, e142.
8. Schlee, M., Hartmann, G., (2016) *Nat. Rev. Immunol.* 16, 566.
9. Pardi, N. et al., (2018) *Nat. Rev. Drug Discov.* 17, 261.
10. Mu, X., Hur, S., (2021) *Acc. Chem. Res.* 54, 4012.
11. Weissman, D. et al., (2013) *Methods Mol. Biol.* 969, 43.
12. Kalkmakoff J., Payne C.C., (1973) *Anal. Biochem.* 55, 26.
13. Baierdörfer M. (2019) *Mol. Ther. Nucleic Acids.* 15, 26.
14. Sambrook, J. et al., (1989) *Molecular Cloning: A Laboratory Manual* (2nd ed.), New York, Cold Spring Harbor Laboratory Press.

TECHNICAL APPENDIX
A. Electrophoretic Mobility of N1meΨ-RNA in Denaturing Agarose

While Ψ-RNA displays altered mobility during electrophoresis as compared to the comparable U-RNA of identical sequence, the mobility of N1meΨ-RNA is much more comparable to that of U-RNA. Thus N1meΨ-RNA can be sized against a U-RNA molecular weight ladder more accurately.

B. ABBREVIATED INCOGNITO T7 mSCRIPT COMPLETE N1meΨ-mRNA PRODUCTION PROCEDURE for experienced kit users.

Synthesis of IVT N1meΨ-RNA and DNase I Treatment of IVT Reaction

- Combine the following at room temperature in the order given.

x	μl	RNase-Free Water
1	μg	linearized template DNA with T7 promoter
2	μl	10X T7 mScript Transcription Buffer II
7.2	μl	N1meΨTP PreMix
2	μl	100 mM DTT
0.5	μl	ScriptGuard RNase Inhibitor
2	μl	T7 mScript Enzyme Solution
20	μl	Total reaction volume.....Incubate at 37°C for 15-30 minutes.
- Add 1 μl RNase-Free DNase I, Incubate at 37°C for 15 minutes.

IVT RNA Purification

- Add 29 μl of RNase-Free Water and mix; add 50 μl of 5 M ammonium acetate and mix; incubate on ice, 4°C, or –20°C for 10-15 minutes; Collect by centrifugation; Wash pellet with 70% ethanol; Resuspend RNA in 50-75 μl RNase-Free Water; Quantitate RNA.

Synthesis of Capped N1meΨ-RNA

- Heat Denature the RNA, In one tube, combine the following reaction components:

x	μl	RNase-Free Water
≤69.5	μl	<i>In vitro</i> transcribed N1meΨ-RNA (50-60 μg RNA)
69.5	μl	Total volume
- Incubate at 65°C for 5-10 minutes. Transfer the tube immediately to ice.
- While the heat-denatured RNA is cooling on ice, make a Cocktail by combining the following reaction components together in a separate tube.

10	μl	10X ScriptCap Capping Buffer
5	μl	20 mM GTP
5	μl	20 mM SAM
2.5	μl	ScriptGuard RNase Inhibitor
4	μl	ScriptCap 2'-O-Methyltransferase (optional)
26.5	μl	Total volume

7. **Just prior to** combining the mixtures from Steps 4 and 6, add the ScriptCap Capping Enzyme to the mixture from Step 6, then combine this mixture with the mixture from Step 4.

26.5	μl	Cocktailed reaction components (from step 6)	
4	μl	ScriptCap Capping Enzyme	
69.5	μl	Heat-denatured RNA (from step 4)	
100	μl	Total reaction volume	Incubate at 37°C for ≥30 minutes.

Synthesis of Poly(A)-Tailed N1meΨ-RNA

8. Combine the following at room temperature in the order given.

100	μl	5'-Capped <i>In vitro</i> transcribed RNA (from Step 7)	
0.5	μl	ScriptGuard RNase Inhibitor	
12	μl	10X A-Plus Poly(A) Tailing Buffer	
6	μl	20 mM ATP	
5	μl	A-Plus Poly(A) Polymerase	
123.5	μl	Total reaction volume.....	Incubate at 37°C for 30 minutes.

Purification of the Capped and Tailed N1meΨ-mRNA

9. Add 124 μl of 5 M ammonium acetate and mix; incubate on ice, 4°C, or –20°C for 10-15 minutes; Collect by centrifugation; Wash pellet with 70% ethanol; Resuspend RNA in 60 μl RNase-Free Water; Quantitate RNA.

Min-Immune Gold dsRNA Removal Treatment

10. Save an amount of untreated RNA to run on a denaturing agarose gel versus the treated RNA for post treatment RNA analysis.

Combine the following at room temperature in the order given.

x	μl	RNase-Free Water	
12	μl	Min-Immune Gold 10X RNase III Treatment Buffer	
3	μl	ScriptGuard RNase Inhibitor	
y	μl	60 μg mScript N1meΨ-mRNA	
6	μl	Min-Immune Gold RNase III (20X)	
120	μl	Total reaction volume.....	Incubate at 37°C for 60 minutes.

Purification of the Capped & Tailed mScript Complete N1meΨ-mRNA

11. Add 120 μl of 5 M ammonium acetate and mix; incubate on ice, 4°C, or –20°C for 10-15 minutes; Collect by centrifugation; Wash pellet with 70% ethanol; Resuspend RNA in 30-60 μl RNase-Free Water; Quantitate RNA.

C. Clean-up of Problematic IVT Templates

Templates that give low yields or less than full-length transcripts may contain RNase or other contaminants. Such templates usually give better results after the following treatment:¹⁴ Alternatively, see RNA Purification Section III (next page), skip step 4.

- 1) Add Proteinase K to 100-200 µg/ml and SDS to 0.5%.
- 2) Incubate for 30-60 minutes at 37°C.
- 3) Extract with an equal volume of a 1:1 mixture of TE-saturated phenol/chloroform.
- 4) Ethanol precipitate.
- 5) Gently remove the supernatant and rinse the pellet with 70% ethanol.
- 6) Resuspend in RNase-Free TE Buffer.

D. RNA Purification

Purify the RNA by your preferred method. The method chosen should remove residual proteins and unincorporated NTPs from the RNA. Several options are listed below. RNA can be stored at –20°C or –70°C. If the RNA is to be stored indefinitely, store the RNA as an ethanol pellet.

- I) **Organic Extraction / Ammonium Acetate Precipitation:** Removes all proteins and selectively precipitates RNA, leaving most of the unincorporated NTPs in the supernatant. Note: for this method, the RNA to be purified must be >100 bases in size.
 - 1) Add one volume of TE-saturated phenol/chloroform. Vortex vigorously for 10 seconds.
 - 2) Spin in a microcentrifuge at >10,000 x g for 5 minutes to separate the phases.
 - 3) Remove the aqueous (upper) phase with a pipette and transfer to a clean tube.
 - 4) Add one volume of 5 M ammonium acetate, mix well then incubate for 15 minutes on ice.
 - 5) Pellet the RNA by centrifugation at >10,000 x g for 15 minutes at 4°C.
 - 6) Remove the supernatant with a pipette and gently rinse the pellet with 70% ethanol.
 - 7) Remove the 70% ethanol with a pipette without disturbing the RNA pellet.
 - 8) Allow pellet to dry, then resuspend in RNase-Free Water, TE or other suitable buffer.
- II) **Ammonium Acetate Precipitation:** Selectively precipitates RNA, while leaving most of the protein and unincorporated NTPs in the supernatant. Note: for this method, the RNA to be purified must be >100 bases in size.
 - 1) Add one volume of 5 M ammonium acetate, mix well.
 - 2) Incubate for 15 minutes on ice.
 - 3) Pellet the RNA by centrifugation at >10,000 x g for 15 minutes at 4°C.
 - 4) Remove the supernatant with a pipette and gently rinse the pellet with 70% ethanol.
 - 5) Remove the 70% ethanol with a pipette without disturbing the RNA pellet.
 - 6) Allow pellet to dry, then resuspend in RNase-Free Water, TE or other suitable buffer.
 - 7) While usually unnecessary, steps 1-6 may be repeated a second time for even cleaner RNA.

- III) **Organic Extraction / Chromatography / Ethanol Precipitation:** Removes all proteins and unincorporated NTPs from the RNA.
- 1) Add one volume of TE-saturated phenol/chloroform. Vortex vigorously for 10 seconds.
 - 2) Spin in a microcentrifuge at $>10,000 \times g$ for 5 minutes to separate the phases.
 - 3) Remove the aqueous (upper) phase with a pipette and transfer to a clean tube.
 - 4) Remove unincorporated NTPs by spin column chromatography.¹⁴ For commercially-available columns, follow the manufacturer's instructions for this step. Recover the RNA in $\sim 100 \mu\text{l}$.
 - 5) Add one-tenth volume of 3 M sodium acetate and 2.5 volumes of 95% ethanol to the tube, mix well.
 - 6) Incubate for 15 minutes on ice.
 - 7) Pellet the RNA by centrifugation at $>10,000 \times g$ for 15 minutes at 4°C .
 - 8) Remove the supernatant with a pipette and gently rinse the pellet with 70% ethanol.
 - 9) Remove the 70% ethanol with a pipette without disturbing the RNA pellet.
 - 10) Allow pellet to dry, then resuspend in RNase-Free Water, TE or other suitable buffer.
- IV) **RNA-Binding Purification Column:** Several options are available commercially from multiple vendors. Follow the manufacturer's recommended protocol. The final resuspension of RNA should be in RNase-Free Water, TE or other suitable buffer.

E. Synthesis of IVT N1meΨ-RNA with Minimal Amounts of T7 mScript Enzyme Solution

The *In Vitro* Transcription and Common Usage Modules are required for this portion of the procedure.

1. Set up the IVT reaction at room temperature.
Add the reagents in the order listed below.

Alternate INCOGNITO mScript IVT Reaction	
Component	Amount
RNase-Free Water	x μl
Linearized template DNA with T7 RNAP promoter	1 μg
10X T7 mScript Transcription Buffer II	2 μl
N1meΨTP PreMix	7.2 μl
100 mM DTT	2 μl
ScriptGuard RNase Inhibitor	0.5 μl
T7 mScript Enzyme Solution	0.6 μl
Total Reaction Volume	20 μl

2. Incubate at 37°C for 1-2 hours.

Important Assemble transcription reactions at room temperature in the order indicated at left. Assembly of transcription reactions at <22°C or in an alternate order, can result in the formation of an insoluble precipitate.



Transcription Buffer stored at –70°C may result in the formation of a white precipitate. To dissolve it, heat the tube at 37°C for 5 minutes and mix thoroughly.



One microgram of DNA template is recommended for most reactions. If the DNA template is <0.16 μg/μl, concentrate it, then resuspend in the appropriate amount of RNase-Free Water.

Important Use a 2 hour incubation when transcribing a template for the first time. Shorter incubation times can be used for subsequent transcription reactions once the yield characteristics of the template have been defined.

F. Synthesis of Capped N1meΨ-RNA with Minimal Amounts of ScriptCap Capping Enzymes

The Post-Transcriptional Capping and Common Usage Modules are required for this portion of the procedure.

1. The protocol below was designed to build a Cap 1 structure on 5' end of 50-60 µg of uncapped RNA. **If a Cap 0 structure is desired**, replace the ScriptCap 2'-O-Methyltransferase in Step 3 with an equivalent volume of RNase-Free Water.

Combine the following reagents:

Alternate INCOGNITO mScript Capping Reaction (step 1)	
Component	Amount
RNase-Free Water	x µl
<i>In vitro</i> transcribed N1meΨ-RNA, 50-60 µg	≤74.5 µl
Total Volume	74.5 µl



Heat-denaturation of the RNA is an optional step, but it is strongly recommended for RNAs which have not previously been characterized for their ease of enzymatic capping.

Important Only heat-denature the RNA and water components. **Do not** include any other reagent in this step.

2. Incubate at 65°C for 5-10 minutes, then transfer to ice.
3. While the heat-denatured RNA is cooling on ice, prepare a "Cocktail" of the following reaction components together in a separate tube.

Alternate INCOGNITO mScript Capping Reaction (step 3)	
Component	Amount
10X ScriptCap Capping Buffer	10 µl
20 mM GTP	5 µl
20 mM SAM	5 µl
ScriptGuard RNase Inhibitor	2.5 µl
ScriptCap 2'-O-Methyltransferase (100 U/µl optional)	2 µl
Total Volume	24.5 µl



Important Do not include the ScriptCap Capping Enzyme in this mix.

Important Keep the thawed stock SAM solution on ice.



A white precipitate may form in the 10X ScriptCap Capping Buffer upon storage. To dissolve it, heat the tube at 37°C for 5 minutes and mix thoroughly.



If a Cap 0 structure is desired, replace the ScriptCap 2'-O-Methyltransferase with RNase-Free Water.

4. **Just prior to starting the reaction**, add the ScriptCap Capping Enzyme to the Cocktail from Step 3 and then combine this with the uncapped RNA solution from Step 1.

Alternate INCOGNITO mScript Capping Reaction (step 4)	
Component	Amount
Cocktailed reaction components (from step 3)	24.5 µl
ScriptCap Capping Enzyme (10 U/µl)	1 µl
Heat-denatured RNA (from step 1)	74.5 µl
Total Reaction Volume	100 µl



The efficiency of 2'-O-methylation can be lower if the RNA 5' end is structured. If your RNA is not completely 2'-O-methylated, we recommend using the standard protocol. Also, since the concentration of methylation sites for a given mass is higher for small RNA than for large RNA, we recommend using the standard protocol if your RNA is <730 nucleotides in length.

5. Incubate at 37°C for 2 hours.

6. Proceed directly to 3'-Poly(A)-Tailing. Purification of the RNA prior to the tailing step is NOT necessary. Alternatively, the unpurified capped RNA can be frozen and stored overnight at -20°C .

G. Synthesis of Poly(A)-Tailed RNA with Minimal Amounts of A-Plus Poly(A) Polymerase

The Poly(A)-Tailing and Common Usage Modules are required for this portion of the procedure.

1. The protocol below was designed to produce ~150 b long poly(A) tails on 60 µg of capped RNA.
Combine the following reagents:

Alternate mScript Poly(A)-Tailing Reaction	
Component	Amount
5'-Capped <i>In vitro</i> transcribed RNA (from Step D6, page 12 or Step F6, page 29)	100 µl
ScriptGuard RNase Inhibitor	0.5 µl
10X A-Plus Poly(A) Tailing Buffer	12 µl
20 mM ATP	6 µl
A-Plus Poly(A) Polymerase (4 U/µl)	1.8 µl
Total Volume	123.5 µl

Important Do not heat-denature the 5'-Capped *In vitro* transcribed RNA.



To extend the poly(A) tail to >200 b, we recommend using the standard protocol.

2. Incubate at 37°C for 2 hours.
3. Stop the reaction using any one of the following methods:
- Proceed directly to Step F, Purification of the Capped and Tailed N1meΨ-mRNA (page 13).
 - Immediate storage at -20°C or -70°C .
 - Add of EDTA to a final concentration of >11 mM.

Important Do not stop the reaction by heat denaturation because it may degrade the RNA.

H. Min-Immune Gold dsRNA Removal Treatment

We do not recommend a minimal enzyme treatment for the removal of dsRNA. Follow the standard protocol for this step. See page 18.

LIMITED LABEL LICENSE

CELLSCRIPT™'s INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System ("Product") is for making N1meΨ-mRNA having reduced innate immunogenicity in mammalian cells. This Product and the compositions and methods and uses thereof are covered by WIPO PCT Patent Application Numbers WO2007024708A2 and WO2011071931A2 and U.S. Patent Numbers US8278036B2 and US9750824B2, and U.S. and international divisional, continuation, or other patents and patent applications derived therefrom that are owned by the University of Pennsylvania and licensed to CELLSCRIPT™.

The **Min-Immune™ Gold dsRNA Removal Module** of this **Product** effectively removes double-stranded RNA contaminants that are generated as by-products of making mRNA using a process comprising *in vitro* transcription (IVT) of a DNA template encoding said mRNA. This Module and the compositions and methods and uses thereof are covered by WIPO PCT Patent Application Number WO2013102203A2 and U.S. Patent Number US12059479B2 and U.S. and international divisional, continuation, or other patents and patent applications derived therefrom that are owned by CELLSCRIPT.

By purchasing Product from CELLSCRIPT or an authorized distributor of CELLSCRIPT (herein, "**Purchaser**"), Purchaser receives a limited non-exclusive, non-transferable, non-sublicensable right ("**Limited License**") to use the purchased Product solely for its own internal laboratory research use (the "**Licensed Use**") and Purchaser agrees to cite the name of the Product and CELLSCRIPT as its source in any verbal or written public disclosure about said Licensed Use. The **Licensed Use expressly excludes any Commercial Use comprising [A]** any diagnostic, prophylactic, clinical, therapeutic or other use in humans, **[B]** any veterinary, livestock, agricultural use in animals, **[C]** making or using N1meΨ-mRNA encoding transcription factors or cell reprogramming factors to generate human induced pluripotent stem cells (iPSCs), hematopoietic stem or progenitor cells, neurons, immune cells or any other differentiated cells, **and/or [D]** manufacture, distribution, importation, exportation, or sale of any other products and/or services made using Product for which Purchaser receives compensation of any kind, **it being understood that [A]–[D] are separately and/or collectively defined as a "Commercial Use"** herein. No other license rights are granted, expressly or implied, to make, have made, import, export, use, reverse engineer, transfer, offer for sale, or sell Product or any other CELLSCRIPT product or service. By purchase of Products, Purchaser agrees not to make, have made, import, export, use, reverse engineer, transfer, offer for sale, or sell Products, components of Products, or derivatives of Products, or to provide services, information, or data obtained by the use thereof in exchange for money or other consideration. CELLSCRIPT provides no warranties (statutory or implied) concerning non-infringement of intellectual property rights of any other parties, and all such warranties are expressly disclaimed. This Limited License terminates automatically if Purchaser breaches any of the terms herein.

The license remains in effect if the product is being used in accordance with the license terms. The license is terminated immediately upon user's breach of any of the license terms, such as using the product for commercial purposes without proper authorization.

If your organization is interested in using INCOGNITO™ T7 mScript™ Complete N1meΨ-mRNA Production System or any other in CELLSCRIPT products for a Commercial Use, whether in catalog or custom sizes, please contact (CustomerService@cellscript.com) with a description of your interest and needs.

Research Use Label License

INCOGNITO™ kits or other products or services comprising N1-methyl-pseudouridine, pseudouridine, 5-methyl-cytidine and/or other modified nucleotides for use in making RNA or mRNA that are covered by technologies and IP disclosed in U.S. Patent Nos. 8,278,036 and 9,750,824 and PCT Publ. Nos. WO 2007/024708 and WO/2011/071931 and U.S. and international divisional, continuation, or other patents and patent applications derived therefrom that are owned by the University of Pennsylvania and licensed to CELLSRIPT ("Products") are sold for research use only.

By purchasing these Products from CELLSRIPT or an authorized distributor of CELLSRIPT, Purchaser receives a limited non-exclusive, non-transferable right to use the Products purchased from CELLSRIPT solely for its own internal laboratory research use (the "Product Use"). Such Product Use expressly excludes any Commercial Use comprising [A] clinical or other use in humans, [B] veterinary, livestock, agricultural or commercial use in animals, and/or [C] manufacture, distribution, importation, exportation, or sale of any products and/or services made using Products, it being understood that [A]–[C] are separately and/or collectively defined as a "Commercial Use" herein. By purchase of Products, Purchaser agrees not to make, import, use, transfer, offer for sale, or sell Products, components of Products, or derivatives of Products, including modified nucleoside-containing RNA or cells made by use of Products, or to provide services, information, or data obtained by the use thereof in exchange for money or other consideration. CELLSRIPT provides no warranties (statutory or implied) concerning non-infringement of intellectual property rights of any other parties, and all such warranties are expressly disclaimed. Please contact CELLSRIPT to inquire about a license for a Commercial Use.

The license remains in effect as long as the product is being used in accordance with the license terms. The license is terminated if the user breaches any of the license terms, such as using the product for commercial purposes without proper authorization.

The performance of this product is guaranteed for one year from the date of purchase.

Syngene is a registered trademark of Synoptics Ltd Corp, Cambridge, United Kingdom.

Triton is a registered trademark of Rohm & Haas, Philadelphia, Pennsylvania.

A-Plus, CELLSRIPT, EZ-QC, INCOGNITO, Min-Immune, mScript, ScriptCap and ScriptGuard are trademarks of CELLSRIPT, Madison, Wisconsin.

The Purchaser of this product agrees to the TERMS AND CONDITIONS posted on CELLSRIPT's website: <http://www.cellscript.com>.

© 2025 CELLSRIPT, All rights reserved.